219311-44-1
219311-44-1 structure
- Name: Dabuzalgron
- Chemical Name: N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methylphenyl]methanesulfonamide
- CAS Number: 219311-44-1
- Molecular Formula: C12H16ClN3O3S
- Molecular Weight: 317.79200
- Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
- Create Date: 2018-08-19 18:47:14
- Modify Date: 2024-01-07 02:57:50
-
Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function[1].
| Name | N-[6-chloro-3-(4,5-dihydro-1H-imidazol-2-ylmethoxy)-2-methylphenyl]methanesulfonamide |
|---|---|
| Synonyms |
Dabuzalgron
Ro-115-1240 UNII-LGX4GZ74WO |
| Description | Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function[1]. |
|---|---|
| Related Catalog | |
| Target |
α-1A adrenergic receptor[1] |
| In Vitro | Dabuzalgron treatment increases ERK phosphorylation in a dose-dependent fashion with an EC50 of 4.8 μM. ERK1/2 activation contributes to the cardioprotective effects of Dabuzalgron[1]. Dabuzalgron (10 μM; 4 hours) protects NRVMs from cell death due to Doxorubicin (DOX)[1]. Activation of the α1A-AR with Dabuzalgron (10 μM; 4 hours) mitigates the detrimental effects of DOX on mitochondrial membrane potential and abrogates the activation of important elements of the apoptotic response to mitochondrial damage[1]. Western Blot Analysis[1] Cell Line: Neonatal rat ventricular myocytes (NRVMs) Concentration: 0.1 μM, 1 μM, 10 μM and 100 μM Incubation Time: 15 minutes Result: Increased ERK phosphorylation in a dose-dependent fashion with an EC50 of 4.8 μM. |
| In Vivo | Dabuzalgron (10 μg/kg; oral gavage; twice daily; for 7 days; C57Bl6J wild-type or α1A-AR knockout mice) treatment protects against DOX cardiotoxicity by activating the α1A-AR. Dabuzalgron protects against the reduction in transcripts related to mitochondrial function, up-regulates PGC1α, preserves ATP content, and reduces oxidative stress in the hearts of mice treated with DOX[1]. Animal Model: Male C57Bl6J wild-type (WT) or α1A-AR knockout (AKO) mice (8-12-week-old) injected with Doxorubicin (DOX)[1] Dosage: 10 μg/kg Administration: Oral gavage; twice daily; for 7 days Result: Preserved contractile function and reduced fibrosis after DOX administration. AKO mice treated with DOX had worse survival and more profoundly impaired contractile function than WT mice. Protected against the reduction in transcripts related to mitochondrial function, preserved ATP content, and reduced oxidative stress in the hearts of mice treated with DOX. |
| References |
| Density | 1.46 |
|---|---|
| Boiling Point | 521.1ºC at 760mmHg |
| Molecular Formula | C12H16ClN3O3S |
| Molecular Weight | 317.79200 |
| Flash Point | 268.9ºC |
| Exact Mass | 317.06000 |
| PSA | 88.17000 |
| LogP | 2.31860 |
| Vapour Pressure | 5.88E-11mmHg at 25°C |
| Index of Refraction | 1.629 |
| Storage condition | 2-8°C |